Skip to main content
. 2022 Jan 26;8(4):eabj3671. doi: 10.1126/sciadv.abj3671

Fig. 7. HERV-specific T cells are present among tumor-infiltrating T cells.

Fig. 7.

(A) Representative panels of dextramer staining for the six HERV epitopes in TILs from three HLA-2–positive patients with TNBC. Dextramer-positive cells were gated on CD8+ T cells. Negative control: Dextramer complexed to a non-natural irrelevant peptide (ALIAPVHAV). (B) Result summary of dextramer CD8+ T cell detection among TILs from 11 HLA-A2–positive patients with TNBC for the six HERV peptides. (C) Overall survival according to 18-HERV score in TCGA HLA-A2 TNBC patients (n = 65). Patients were divided in three groups according to the score terciles: blue line, high expression (n = 22); green line, intermediate expression (n = 21); red line, low expression (n = 22). (D) Pictures (60×) of TNBC organoids cocultured with CMV-, P1-, or P6-specific CD8+ T cell clones (top-down) acquired at different time points using Nanolive technology. T cells are shown by yellow arrows.